Evogene Partners with Tel Aviv University BCDD to Advance Small-Molecule Drug Discovery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Evogene and the Blavatnik Center for Drug Discovery, BCDD, at Tel Aviv University announced a strategic joint initiative aimed at accelerating the growth, development, and success of innovation originating from Israel's academic research ecosystem and focused on small-molecule drug discovery. This collaboration agreement was facilitated by Ramot, Tel Aviv University's tech transfer company. The initiative is designed to support scientific entrepreneurs and research teams that possess deep biological understanding of novel disease targets but often face significant challenges in translating these discoveries into viable drug development programs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVGN
Wall Street analysts forecast EVGN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.425
Low
2.50
Averages
2.50
High
2.50
Current: 0.425
Low
2.50
Averages
2.50
High
2.50
About EVGN
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Supporting Israel's Academic Innovation Ecosystem
- Strategic Collaboration Initiated: Evogene and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University have entered into a strategic collaboration agreement aimed at accelerating innovation and development in small-molecule drug discovery within Israel's academic research ecosystem, enhancing global competitiveness.
- Tech Transfer Support: This partnership, facilitated by Ramot, Tel Aviv University's tech transfer company, exemplifies the close integration of academia and industry, promoting the commercialization of research outcomes and enhancing Israel's innovative capacity in the biopharmaceutical sector.
- Computational Chemistry and AI Application: Evogene will leverage its advanced capabilities in computational chemistry and artificial intelligence to optimize the design process of small molecules, thereby improving R&D efficiency and reducing time-to-market, which enhances market responsiveness.
- Economic Growth Promotion: By supporting academic innovation and technology transfer, this collaboration is expected to create new growth opportunities for Israel's biotechnology industry, further solidifying the country's position in the global pharmaceutical market.
See More
Supporting Israel's Academic Innovation Ecosystem
- Strategic Collaboration Launched: Evogene and the Blavatnik Center for Drug Discovery at Tel Aviv University have announced a strategic partnership aimed at accelerating small-molecule drug discovery within Israel's academic research ecosystem, combining advanced AI-driven computational chemistry with experimental validation capabilities to enhance drug development success rates.
- Integrated Technology Advantage: By integrating Evogene's ChemPass AI™ generative engine with BCDD's experimental infrastructure, the collaboration will develop a Design-Make-Test-Analyze (DMTA) workflow that significantly improves early-stage drug development efficiency and reduces associated risks.
- Resource Sharing Mechanism: This partnership will provide scientific entrepreneurs and research teams with comprehensive access to both computational and experimental resources, helping them overcome challenges in translating scientific discoveries into viable drug development projects, thereby enhancing Israel's competitiveness in the global drug development arena.
- Driving Innovation Translation: Evogene's CEO Ofer Haviv emphasized that this collaboration will effectively broaden the pipeline of drug candidates, facilitating the translation of breakthrough discoveries from Israel's academic institutions into successful therapeutic solutions, ultimately improving patient treatment outcomes.
See More
Evogene to Showcase New Technologies at BIO International Convention
- Conference Highlights: Evogene Ltd. will showcase its latest achievements in the pharmaceutical sector at the BIO International Convention scheduled for June 22-25, 2026, in San Diego, USA, which is expected to attract significant industry attention.
- Leadership Attendance: The company will be represented by CEO Ofer Haviv, Chief Development Officer Dr. Gabi Tarcic, and VP of Business Development Dr. Olga Nissan, who will present technological breakthroughs in AI-driven small molecule discovery and optimization.
- Technical Presentation: Dr. Tarcic will deliver an oral presentation focusing on how ChemPass AI™ is enabling new collaborative drug discovery opportunities with pharmaceutical and biotech partners, further solidifying Evogene's leadership position in the industry.
- One-on-One Meetings: Evogene's management will be available for one-on-one meetings during the conference, encouraging interested parties to contact the company's investor or public relations team to explore potential collaboration opportunities.
See More
EverGen Infrastructure Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: EverGen Infrastructure reported a 38% year-over-year revenue increase to $2.6 million in Q1 2026, although it saw a decline compared to Q4 2025, indicating strong market performance.
- Debt Restructuring Impact: The company successfully restructured its debt, moving approximately $13 million from corporate to asset level, saving about $500,000 annually in debt service costs, thereby enhancing flexibility for future growth.
- Long-Term Contract Assurance: The 20-year offtake agreement with FortisBC provides a stable revenue base, ensuring long-term revenue certainty and delivering consistent returns for shareholders.
- Sustained Production Capacity: RNG production remained steady at 200,000 gigajoules in Q1 2026, demonstrating strong operational performance despite the lengthy permitting process for expansion projects, which positions the company competitively in the market.
See More
Evogene's BMC128 Phase 1 Clinical Trial Shows Promising Results
- Successful Clinical Trial: Evogene has completed the first-in-human Phase 1 clinical trial of BMC128, enrolling 11 patients, with results indicating a favorable safety profile and high tolerability, as no dose-limiting toxicities were observed, marking a significant milestone for the product's potential in tumor immunotherapy.
- Preliminary Anti-Tumor Activity: Among the 11 patients, 5 achieved stable disease after 16 weeks of combination treatment, and 1 patient experienced a partial response, demonstrating early signs of anti-tumor activity for BMC128 when used alongside immune checkpoint inhibitors, potentially offering new hope for future treatments.
- Biomarker Analysis: Clinical observations aligned with translational analyses, showing increased microbiome diversity and significant evidence of immune activation in responding patients, supporting the proposed mechanism of action for BMC128 and laying a foundation for future clinical applications.
- Strategic Partnership Advancement: Evogene has entered into a licensing agreement with Lishan Biotech to further develop BMC128, reflecting the company's confidence in microbiome-based therapies for cancer treatment and indicating an acceleration in the planning for subsequent clinical development stages.
See More
Evogene Reports Q1 2026 Financial Results and Strategic Developments
- Financial Overview: Evogene reported revenues of $334,000 for Q1 2026, a significant drop from $2.34 million in Q1 2025, indicating challenges in revenue growth that may impact investor confidence.
- R&D Collaboration Expansion: The company announced three new collaborations in the pharmaceutical sector, bringing the total to four, demonstrating Evogene's ongoing commitment to advancing small-molecule discovery and optimization despite its poor financial performance.
- Agricultural Project Progress: The AgPlenus subsidiary is advancing novel herbicide programs through collaboration with Corteva, while its internal fungicide program shows strong progress, highlighting the effective integration of AI-driven design with experimental validation, potentially providing a competitive edge in the market.
- Strategic Transformation and Outlook: Following the strategic transformation initiated in 2025, Evogene is now focused on execution, expecting to support long-term growth through enhanced technological collaborations and product pipeline expansion, despite currently facing financial losses.
See More
Supporting Israel's Academic Innovation Ecosystem
- Strategic Collaboration Initiated: Evogene and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University have entered into a strategic collaboration agreement aimed at accelerating innovation and development in small-molecule drug discovery within Israel's academic research ecosystem, enhancing global competitiveness.
- Tech Transfer Support: This partnership, facilitated by Ramot, Tel Aviv University's tech transfer company, exemplifies the close integration of academia and industry, promoting the commercialization of research outcomes and enhancing Israel's innovative capacity in the biopharmaceutical sector.
- Computational Chemistry and AI Application: Evogene will leverage its advanced capabilities in computational chemistry and artificial intelligence to optimize the design process of small molecules, thereby improving R&D efficiency and reducing time-to-market, which enhances market responsiveness.
- Economic Growth Promotion: By supporting academic innovation and technology transfer, this collaboration is expected to create new growth opportunities for Israel's biotechnology industry, further solidifying the country's position in the global pharmaceutical market.
See More
Supporting Israel's Academic Innovation Ecosystem
- Strategic Collaboration Launched: Evogene and the Blavatnik Center for Drug Discovery at Tel Aviv University have announced a strategic partnership aimed at accelerating small-molecule drug discovery within Israel's academic research ecosystem, combining advanced AI-driven computational chemistry with experimental validation capabilities to enhance drug development success rates.
- Integrated Technology Advantage: By integrating Evogene's ChemPass AI™ generative engine with BCDD's experimental infrastructure, the collaboration will develop a Design-Make-Test-Analyze (DMTA) workflow that significantly improves early-stage drug development efficiency and reduces associated risks.
- Resource Sharing Mechanism: This partnership will provide scientific entrepreneurs and research teams with comprehensive access to both computational and experimental resources, helping them overcome challenges in translating scientific discoveries into viable drug development projects, thereby enhancing Israel's competitiveness in the global drug development arena.
- Driving Innovation Translation: Evogene's CEO Ofer Haviv emphasized that this collaboration will effectively broaden the pipeline of drug candidates, facilitating the translation of breakthrough discoveries from Israel's academic institutions into successful therapeutic solutions, ultimately improving patient treatment outcomes.
See More
Evogene to Showcase New Technologies at BIO International Convention
- Conference Highlights: Evogene Ltd. will showcase its latest achievements in the pharmaceutical sector at the BIO International Convention scheduled for June 22-25, 2026, in San Diego, USA, which is expected to attract significant industry attention.
- Leadership Attendance: The company will be represented by CEO Ofer Haviv, Chief Development Officer Dr. Gabi Tarcic, and VP of Business Development Dr. Olga Nissan, who will present technological breakthroughs in AI-driven small molecule discovery and optimization.
- Technical Presentation: Dr. Tarcic will deliver an oral presentation focusing on how ChemPass AI™ is enabling new collaborative drug discovery opportunities with pharmaceutical and biotech partners, further solidifying Evogene's leadership position in the industry.
- One-on-One Meetings: Evogene's management will be available for one-on-one meetings during the conference, encouraging interested parties to contact the company's investor or public relations team to explore potential collaboration opportunities.
See More
EverGen Infrastructure Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: EverGen Infrastructure reported a 38% year-over-year revenue increase to $2.6 million in Q1 2026, although it saw a decline compared to Q4 2025, indicating strong market performance.
- Debt Restructuring Impact: The company successfully restructured its debt, moving approximately $13 million from corporate to asset level, saving about $500,000 annually in debt service costs, thereby enhancing flexibility for future growth.
- Long-Term Contract Assurance: The 20-year offtake agreement with FortisBC provides a stable revenue base, ensuring long-term revenue certainty and delivering consistent returns for shareholders.
- Sustained Production Capacity: RNG production remained steady at 200,000 gigajoules in Q1 2026, demonstrating strong operational performance despite the lengthy permitting process for expansion projects, which positions the company competitively in the market.
See More
Evogene's BMC128 Phase 1 Clinical Trial Shows Promising Results
- Successful Clinical Trial: Evogene has completed the first-in-human Phase 1 clinical trial of BMC128, enrolling 11 patients, with results indicating a favorable safety profile and high tolerability, as no dose-limiting toxicities were observed, marking a significant milestone for the product's potential in tumor immunotherapy.
- Preliminary Anti-Tumor Activity: Among the 11 patients, 5 achieved stable disease after 16 weeks of combination treatment, and 1 patient experienced a partial response, demonstrating early signs of anti-tumor activity for BMC128 when used alongside immune checkpoint inhibitors, potentially offering new hope for future treatments.
- Biomarker Analysis: Clinical observations aligned with translational analyses, showing increased microbiome diversity and significant evidence of immune activation in responding patients, supporting the proposed mechanism of action for BMC128 and laying a foundation for future clinical applications.
- Strategic Partnership Advancement: Evogene has entered into a licensing agreement with Lishan Biotech to further develop BMC128, reflecting the company's confidence in microbiome-based therapies for cancer treatment and indicating an acceleration in the planning for subsequent clinical development stages.
See More
Evogene Reports Q1 2026 Financial Results and Strategic Developments
- Financial Overview: Evogene reported revenues of $334,000 for Q1 2026, a significant drop from $2.34 million in Q1 2025, indicating challenges in revenue growth that may impact investor confidence.
- R&D Collaboration Expansion: The company announced three new collaborations in the pharmaceutical sector, bringing the total to four, demonstrating Evogene's ongoing commitment to advancing small-molecule discovery and optimization despite its poor financial performance.
- Agricultural Project Progress: The AgPlenus subsidiary is advancing novel herbicide programs through collaboration with Corteva, while its internal fungicide program shows strong progress, highlighting the effective integration of AI-driven design with experimental validation, potentially providing a competitive edge in the market.
- Strategic Transformation and Outlook: Following the strategic transformation initiated in 2025, Evogene is now focused on execution, expecting to support long-term growth through enhanced technological collaborations and product pipeline expansion, despite currently facing financial losses.
See More
